A phase II, open label, preoperative study to assess the efficacy of the novel steroid sulfatase inhibitor Irosustat in postmenopausal women with early oestrogen receptor positive breast cancer.

Trial Profile

A phase II, open label, preoperative study to assess the efficacy of the novel steroid sulfatase inhibitor Irosustat in postmenopausal women with early oestrogen receptor positive breast cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Irosustat (Primary)
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms IPET
  • Most Recent Events

    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 11 Mar 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
    • 30 Sep 2014 Planned End Date changed from 1 Aug 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top